BioMark Diagnostics (BUX) AI Stock Analysis

• Market Cap: C$22.72M
• Dividend Yield: N/A
• Average Volume (3M): 8.25K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.46
• Revenue Growth: -4.98%
• EPS Growth: -13.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 65
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.02
• Shares Outstanding: 90,886,230
• 10 Day Avg. Volume: 5,250
• 30 Day Avg. Volume: 8,250
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 146.68
• Price to Cash Flow (P/CF): -14.20
• P/FCF Ratio: 349.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

BioMark Diagnostics has a challenging financial position with persistent losses and high leverage, leading to a low financial performance score. However, recent funding has bolstered its financial capacity, supporting commercialization and growth initiatives. The technical indicators show strong momentum, although care is warranted due to overbought conditions. Valuation remains unattractive given the negative P/E. Overall, while there are positive developments, significant financial and operational challenges persist.

BioMark Diagnostics Business Overview & Revenue Model

Company Description

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

How the Company Makes Money

BioMark Diagnostics makes money through the commercialization of its diagnostic tests and platforms. The company generates revenue by selling its diagnostic kits to healthcare providers, hospitals, and laboratories. Additionally, BioMark may engage in licensing agreements with other biotech and pharmaceutical companies, allowing them to use its proprietary technology for cancer diagnostics. Revenue streams also include potential collaborations and partnerships with academic institutions and research organizations to further develop and validate its diagnostic technologies. These partnerships can provide funding and shared resources, contributing to the company's overall earnings.

BioMark Diagnostics Financial Statement Overview

Summary

BioMark Diagnostics faces significant financial challenges with negative profitability, high leverage, and negative cash flows. The company shows a weak financial position with a critical need to stabilize revenue and improve operational efficiencies. The negative equity and consistent losses highlight the urgency for strategic financial restructuring.

Income Statement

BioMark Diagnostics shows negative profitability with consistent net losses over the periods analyzed. The gross profit margin and net profit margin are both negative, indicating operating challenges. Revenue growth is also inconsistent, with fluctuations and a recent decline in TTM. Margins for EBIT and EBITDA are deeply negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet reveals high financial leverage with a negative stockholders' equity, indicating potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, and ROE is also negative, highlighting the lack of returns for shareholders. The equity ratio is negative, reinforcing the fragile financial positioning.

Cash Flow

Cash flow analysis shows negative free cash flow, indicating potential liquidity challenges. Operating cash flow remains negative, and the ratios of operating and free cash flow to net income are not favorable. Although financing activities are providing some cash inflow, it is not sufficient to cover operational cash outflows.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
155.03K	163.22K	153.49K	43.93K	0.00	263.28K
	Gross Profit
-3.57K	163.22K	-232.70K	43.93K	-13.69K	263.28K
	EBIT
-1.10M	-1.32M	-1.84M	-1.28M	-1.09M	-1.18M
	EBITDA
-1.52M	-919.05K	-1.35M	-1.22M	-1.08M	-1.20M
	Net Income Common Stockholders
-1.90M	-1.43M	-1.84M	-1.45M	-1.09M	-1.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
88.58K	156.75K	72.04K	382.71K	877.68K	611.80K
	Total Assets
876.63K	1.09M	732.29K	1.47M	952.94K	637.29K
	Total Debt
546.53K	805.93K	823.87K	1.05M	119.32K	8.66K
	Net Debt
457.95K	649.18K	751.83K	666.69K	-758.35K	-603.14K
	Total Liabilities
1.97M	1.70M	1.88M	2.11M	1.03M	1.08M
	Stockholders Equity
-1.10M	-609.61K	-1.15M	-635.69K	-79.09K	-439.13K
Cash Flow		Free Cash Flow
-859.39K	-986.91K	-919.72K	-1.26M	-455.55K	-454.57K
	Operating Cash Flow
-855.64K	-982.52K	-914.42K	-1.20M	-455.55K	-453.79K
	Investing Cash Flow
-3.74K	-4.39K	-5.30K	-59.20K	-3.20K	-790.00
	Financing Cash Flow
634.94K	1.07M	609.05K	768.16K	724.63K	1.05M

BioMark Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BUX, the sentiment is Positive. The current price of 0.25 is below the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.24, and above the 200-day MA of 0.23, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.11 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BUX.

BioMark Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEO	67 Neutral	C$423.68M	―	-3.15%	3.92%	-15.41%	-69.47%
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
BUX	47 Neutral	C$22.72M	―	190.32%	―	-4.98%	-13.59%
PHA	44 Neutral	C$3.89M	―	-160.58%	―	44.96%	-827.30%

BioMark Diagnostics Corporate Events

BioMark Diagnostics Closes Oversubscribed Private Placement to Boost Commercialization

BioMark Diagnostics Inc. announced the successful closing of its oversubscribed private placement, raising CAD $4,261,195 to accelerate commercialization and corporate development. This funding demonstrates strong investor confidence and will support strategic initiatives, including lab certification and personnel hiring, essential for the company’s growth and market expansion.

BioMark Diagnostics Secures $2 Million Investment to Advance Cancer Detection Platform

BioMark Diagnostics Inc. has successfully secured a USD $2 million investment from strategic U.S. investors to advance its early-detection oncology testing platform. This funding will support BioMark’s lab certification, commercialization efforts, team expansion, and U.S. market entry, reflecting strong investor confidence in its innovative cancer diagnostic technology and management team.

BioMark Diagnostics Reaffirms Commitment to Rare Disease Research on Rare Disease Day 2025

BioMark Diagnostics Inc. has reaffirmed its commitment to rare disease research, particularly focusing on challenging conditions such as neuroendocrine tumors of the lung and glioblastoma multiforme. On Rare Disease Day 2025, the company emphasized its dedication to developing advanced diagnostic tools that provide earlier and more accurate diagnoses, thereby empowering clinicians to offer personalized care and improving patient outcomes. By leveraging cutting-edge metabolomics and machine learning technologies, BioMark aims to enhance the sensitivity and specificity of detection for these rare cancers, addressing critical needs and closing the diagnostic gap for rare disease patients.